Maller, J., S. George, S. Purcell, J. Fagerness, D. Altshuler, M. J. Daly, and J. M. Seddon. 2006. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nature Genetics 38:1055-1059.

Miranda, M. L., J. M. Silva, M. A. Overstreet Galeano, J. P. Brown, D. S. Campbell, E. Coley, C. S. Cowan, D. Harvell, J. Lassiter, J. L. Parks, and W. Sandele. 2005. Building geographic information system capacity in local health departments: Lessons from a North Carolina project. American Journal of Public Health 95(12):2180-2185.

Modeste, N. N. 1996. Dictionary of public health promotion and education: Terms and concepts. Thousand Oaks, CA: SAGE Publications.

Nash, J. F. 1950. Equilibrium points in N-person games. Proceedings of the National Academy of Sciences 36:48-49.

NHSE (National Health Service Executive). 1996. Promoting clinical effectiveness: A framework for action in and through the NHS. Leeds, UK: National Health Service Executive.

Nissen, S. E., J. C. Tardif, S. J. Nicholls, J. H. Revkin, C. L. Shear, W. T. Duggan, W. Ruzyllo, W. B. Bachinsky, G. P. Lasala, and E. M. Tazcu. 2007. Effect of torcetrapib on the progression of coronary atherosclerosis. New England Journal of Medicine 356(13):1304-1316.

Oratz, R., D. Paul, A. L. Cohn, and S. M. Sedlacek. 2007. Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. Journal of Oncology Practice 3(4):182-186.

Paik, S., S. Shak, G. Tang, C. Kim, J. Baker, M. Cronin, R. Baehner, M. Walker, D. Watson, T. Park, J. Bryant, and N. Wolmark. 2003. Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients—NSABP studies, B-20 and B-14. San Antonio Breast Cancer Symposium 2003. Abstract #16.

Paik, S., S. Shak, G. Tang, C. Kim, H. Joo, J. Baker, M. Cronin, D. Watson, J. Bryant, J. Costantino, and N. Wolmark. 2004. Expression of the 21 genes in the Recurrence Score assay and prediction of clinical benefit from tamoxifen in NSABP study B-14 and chemotherapy in NSABP study B-20. San Antonio Breast Cancer Symposium 2004. Abstract #24.

Pear, R. 2008 (March 23). Gap in life expectancy widens for the nation. New York Times. http://www.nytimes.com/2008/03/23/us/23health.html (accessed March 25, 2008).

Phillips, K. A., and S. L. Van Bebber. 2004. A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Future Medicine 5(8):1139-1149.

Phillips, K. A., and S. L. Van Bebber. 2005. Measuring the value of pharmacogenomics. Nature Reviews Drug Discovery 4(6):500-509.

Phillips, K. A., D. L. Veenstra, S. Ramsey, S. L. Van Bebber, and J. Sakowski. 2004. Genetic testing and pharmacogenomics: Issues for determining the impact to health care delivery and costs. American Journal of Managed Care 10(7):425-432.

Porter, M. E. 2006. Redefining health care: Creating value-based competition on results. Cambridge, MA: Harvard Business School Press.

Rettenmaier, A. J., and T. R. Saving. 2004. The 2004 Medicare and Social Security trustees reports. National Center for Policy Analysis, Study No. 266. http://www.ncpa.org/pub/st/st266/ (accessed February 12, 2008).

Rieder, M. J., A. P. Reiner, B. F. Gage, D. A. Nickerson, C. S. Eby, H. L. McLeod, D. K. Blough, K. E. Thummel, D. L. Veenstra, and A. E. Rettie. 2005. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. New England Journal of Medicine 352:2285-2293.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement